Genome Editing Market Is Anticipated To Presence Of Strong Pipeline Products Till 2025: Grand View Research, Inc.
The global genome editing market is anticipated to reach USD
8.1 billion by 2025, according to a new report by Grand View Research, Inc. Key
drivers attributing to the expansion include early applications of DNA editing
to therapeutics. Use of the technology for the disease eradication through
direct correction of disturbances in normal physiology, engineering the immune
response, and alteration of pathogen targets in the host is anticipated to
drive the market with substantial opportunities.
The ability of genome editing
therapies to offer a significant improvement over current treatment options is
important in enabling editing technologies to capture significant revenue
share. Improved efficacy, reduced side effects, and the potential for cure for
specific diseases, can be attributed to induce growth in the coming
years.
Moreover, technological
advancements with respect to the development of novel vectors for delivery is
anticipated to fuel growth in the coming years. Rising competition amongst the
operating entities in order to gain the larger share of revenue is also
responsible for the projected growth. These companies leverage industry
collaborations for the acceleration of diversified product pipelines.
UK genome editing market, by
end-use, 2014 - 2025 (USD Million)
Browse full research report on
Genome
Editing Market
Further key findings from
the report suggest:
- There has
been great excitement surrounding the highly adaptable CRISPR technology.
- The increased
ease of retargeting and the ability to multiplex goes a long way toward explaining
the speed with which CRISPR-centric companies have sprung up.
- Ex-vivo mode
of delivery accounted for the largest share of the revenue.
- Therapy
through ex-vivo mode of delivery allow the control over the specific
dosage of therapeutic molecules delivered to cells.
- Cell line
engineering dominated with respect to revenue generation owing to the high
utilization of technology in stem cell engineering.
- There is
comparatively, higher adoption of the technology in the biotechnology and
pharmaceutical organizations for the purpose of therapeutic development.
- Availability
of other services such as gRNA library production and screening service
along with editing is anticipated to propel growth in the outsourcing
services.
- Asia Pacific
is anticipated to witness fastest growth over the forecast period owing to
rising penetration of technology in comparatively immature market.
- Key players
contributing in this market are Thermo Fisher Scientific, Inc., Sangamo,
Editas Medicine, Recombinetics, Inc, Sigma Aldrich Corporation, CRISPR
THERAPEUTICS, Intellia Therapeutics, Inc., Caribou Biosciences, Inc.
- These
participants are capitalizing on unique advantages offered by the nuclease
technology, they are working on.
For
more information: http://www.grandviewresearch.com
Comments
Post a Comment